A/Prof Ashish Bajel
Clinical (Associate Professor)
Department of Medicine
204 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Rhino-sino-orbital and/or central nervous system infections due to Lomentospora prolificans and Scedosporium spp. in onco-haematology patients
DOI: 10.1093/mmy/myag0162026
Journal article
Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia
DOI: 10.1080/10428194.2025.25999912025
Journal article
Consensus guidelines for initial management of neutropenic fever
DOI: 10.1111/imj.702482025
Journal article
Consensus guidelines for the subsequent management of neutropenic fever after empiric therapy
DOI: 10.1111/imj.702492025
Journal article
Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action
DOI: 10.1182/blood-2025-59212021
Journal article
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
DOI: 10.1182/blood.20200101672018
Journal article
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML
DOI: 10.1182/blood-2018-05-852566
RECENT SCHOLARLY WORKS
2025
Journal article
Outcomes of patients with relapsed/refractory FLT3mut Acute Myeloid Leukemia who resumed gilteritinib therapy after HSCT: Post hoc analysis from the ADMIRAL and COMMODORE trials
DOI: 10.1182/blood-2025-422025
Journal article
Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DOI: 10.1182/blood-2025-10442025
Journal article
Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study
DOI: 10.1182/blood-2025-34182025
Journal article
Establishing the impact of effective donor-specific antibody (DSA) desensitisation in haploidentical and mismatched donor haematopoietic stem cell transplants: An Australian experience
DOI: 10.1182/blood-2025-41992025
Journal article
Immunological responses to blinatumomab treatment in B-acute lymphoblastic leukaemia (B-ALL) patients - australasian leukemia and lymphoma group ALL08 blam study
DOI: 10.1182/blood-2025-3341